

Congo





I. Epidemiological profile

Population (UN Population Division)	2017 %
High transmission (>1 case per 1000 population)	5.3M 100
Low transmission (0-1 case per 1000 population)	0 -
Malaria free (0 cases)	0 -
Total	5.3M

Parasites and vectors				
Major plasmodium species:	P.falcipa	rum: 100 (%) ,	P.vivax: 0 (%)	
Major anopheles species:	An. gam	ibiae, An. fune	stus, An. nili, An. mouc	heti
Reported confirmed cases (health fa	acility):	127 939	Estimated cases:	1M [558.9K, 1.7M]
Confirmed cases at community leve	l:	-		
Confirmed cases from private secto	r:	-		
Reported deaths:		229	Estimated deaths:	2K [1.8K, 2.2K]

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/ No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2007
	ITNs/LLINs distributed to all age groups	Yes	2011
IRS	IRS is recommended	Yes	2007
	DDT is used for IRS	No	-
Larval control	Use of Larval Control	No	
IPT	IPT used to prevent malaria during pregnancy	Yes	2006
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2014
	Malaria diagnosis is free of charge in the public sector	No	-
Treatment	ACT is free for all ages in public sector	No	-
	The sale of oral artemisinin-based monotherapies (oAMTs)	is banned	2006
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	No	-
	Primaquine is used for radical treatment of P. vivax	No	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring of adverse reaction to antimalarials exists	No	-
Surveillance	ACD for case investigation (reactive)	No	-
	ACD at community level of febrile cases (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	Yes	-
	Uncomplicated P. vivax cases routinely admitted	No	-
	Case and foci investigation undertaken	No	
	Case reporting from private sector is mandatory	No	-

Antimalaria treatment policy First-line treatment of unconfirmed malaria AS+AQ First-line treatment of P. falciparum AS+AQ For treatment failure of P. falciparum AL Treatment of Severe malaria QN Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ AS+AQ - Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 2.4 4 28 days 5 P. falciparum AS+AQ - Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2011) insecticide class Years (%) sites 1 Vectors 2 Used 3 Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2013 100% (1) An. gambiae s.l. Yes 1-Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2-Principal vectors that exhibited resistance 3	First-line tre						Medicine	Year adopted
First-line treatment of P. falciparum For treatment failure of P. falciparum For treatment of Severe malaria Treatment of Severe malaria QN Treatment of P. vivax QN Treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. No Precent of sites for which resistance confirmed and total number of sites that reported data (n) Principal vectors that exhibited resistance		eatment of un		d malari	,		Λ\$±ΛΩ	
For treatment failure of P. falciparum AL - Treatment of severe malaria QN - Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201) Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2013 0% (1) An. gambiae s.l. Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2 Principal vectors that exhibited resistance							-	
Treatment of Severe malaria Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2011) Insecticide class Years (%) sites Vectors Vectors Used Carbamates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.t. Yes Percent of sites for which resistance confirmed and total number of sites that reported data (n)							-	-
Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2011) Insecticide class Years (%) sites Vectors Vectors Used Anagambiae s.l. No Organophosphates 2013-2014 25% (4) Anagambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) Anagambiae s.l. Yes 1-Percent of sites for which resistance confirmed and total number of sites that reported data (n)			•	1111			· ·=	-
Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n)			ld				QIN	-
Type of RDT used - Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organophosphates 2013-2014 25% (4) An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes 1-Percent of sites for which resistance confirmed and total number of sites that reported data (n)					+ - E D:		-	-
Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) An. gambiae s.L. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.L. Yes 1-Percent of sites for which resistance confirmed and total number of sites that reported data (n)			radical t	reatmen	t of P. VI	vax		
Medicine Year Min Median Max Follow-up No. of studies Species AL 2010-2017 0 0 3.6 28 days 5 P. Falciparum AS+AQ 2010-2017 0 2.4 4 28 days 4 P. Falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201) Insecticide class Years (%) sites Vectors	Type of RDT	used						-
AL 2010-2017 0 0 3.6 28 days 5 $P.$ falciparum AS+AQ 2010-2017 0 2.4 4 28 days 5 $P.$ falciparum Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites 1 Vectors 2 Used 3 Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) $P.$ An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) $P.$ An. gambiae s.l. Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2 Principal vectors that exhibited resistance	Therapeutic	efficacy tests	(clinical	and para	sitologi	cal failure, %	5)	
AS+AQ 2010-2017 0 2.4 4 28 days 4 $P.\ falciparum$ Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites 1 Vectors 2 Used 3 Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) $An.\ gambiae\ s.l.$ No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) $An.\ gambiae\ s.l.$ Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2 Principal vectors that exhibited resistance	Medicine	Year	Min N	4edian	Max	Follow-up	No. of studies	Species
Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (201: Insecticide class Years (%) sites 1 Vectors 2 Used 3 Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes	AL	2010-2017	0	0	3.6	28 days	5	P. falciparum
Insecticide class Years (%) sites¹ Vectors² Used³ Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes Percent of sites for which resistance confirmed and total number of sites that reported data (n) Principal vectors that exhibited resistance	AS+AQ	2010-2017	0	2.4	4	28 days	4	P. falciparum
Carbamates 2013-2014 0% (4) - No Organochlorines 2013-2014 25% (4) An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes	Resistance s	tatus by insec	ticide cla	nss (2010)-2017)	and use of cl	ass for malaria vecto	or control (2017
Organochlorines 2013-2014 25% (4) An. gambiae s.l. No Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2 Principal vectors that exhibited resistance	Insecticide o	class	Year	S	(%)	sites ¹	Vectors ²	Used ³
Organophosphates 2013-2014 0% (4) - No Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes 1 Percent of sites for which resistance confirmed and total number of sites that reported data (n) 2 Principal vectors that exhibited resistance	Carbamates		2013	-2014	0%	(4)	-	No
Pyrethroids 2013-2013 100% (1) An. gambiae s.l. Yes Percent of sites for which resistance confirmed and total number of sites that reported data (n) Principal vectors that exhibited resistance	Organochlori	nes	2013	-2014	25	% (4)	An. gambiae s.l.	No
Percent of sites for which resistance confirmed and total number of sites that reported data (n) Principal vectors that exhibited resistance	Organophosp	hates	2013	-2014	0%	(4)	-	No
² Principal vectors that exhibited resistance	Pyrethroids		2013	-2013	10	0% (1)	An. gambiae s.l.	Yes
² Principal vectors that exhibited resistance	¹ Percent of site	es for which resis	tance conf	irmed and	total num	har of sites the	t reported data (n)	
_ '					totat man	iber or sites the	ic reported data (ii)	
	. '							